The development of radiolabelled ghrelin analogues for the molecular imaging of prostate cancer through targeting the growth hormone secretagogue receptor.

通过靶向生长激素促分泌受体，开发放射性标记的生长素释放肽类似物，用于前列腺癌的分子成像。

• 批准号: 253852
• 负责人: Luyt Leonard G
• 金额: $ 28.61万
• 依托单位: London Regional Cancer Program
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-03-01 至 2015-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=253852&lang=en
• 关键词: Ghrelin; Growth Hormone Secretagogue Receptor; Medicinal Chemistry; Molecular Imaging; Peptide Chemistry; Pet; Radiopharmaceuticals

Prostate cancer is the most commonly diagnosed cancer in Canadian men with over 20,000 cases expected in 2010. Early and accurate diagnosis of the disease is critical for effective treatment planning and especially important is the ability to correctly id

前列腺癌是加拿大男性最常见的癌症，预计2010年将有超过2万例。早期和准确的疾病诊断对有效的治疗计划至关重要，尤其重要的是正确识别